**Appendix Table C28. Time to event outcomes: Comparator, rhabdomyosarcoma**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study (Investigator, country, year)** | **Record Number** | **Group (N)** | **Outcome** | **Med (mos)** | **1 yr** | **2 yr** | **3 yr** | **4 yr** | **5 yr** |
| Breneman, USA, 2003 | 75360 | comparator (127) |   |   | ~85% | ~50% | 39% (30-48) | ~25% | ~25% |
| Carli, Italy, 1999 | 16010 | Comparator (44) | 27.7 (13.3-42.1) 3 year |   | ~66% | ~35% | 27.7 (13.3-42.1) | ~26% | ~26% |
| McDowell, UK, 2010 | 75350 | Comparator (45) |   |   |   |   | 62.14% |   | 47.68% |
| Pappo, USA, 1999 | 48020 | Comparator (605) | 17% (14-21) | 4.7 years (.8-12.6) |   |   |   |   |   |
| Pappo, USA, 2001 | 47860 | Comparator (48) |   |   |   | 46% (31-60) |   |   |   |
| Sandler, USA, 2001 | 12810 | Comparator (152) |   |   | ~75% | ~43% | ~40% | ~34% | ~37.5% |
| Van Winkle, USA, 2005 | 43550 | Comparator(27) |   |   | 56 (10) | 26 (8) |   |   |   |
| Williams, Canada, 2004 | 9010 | Comparator (13) | 15% (-4-35) | 3 year |   |   |   |   |   |

**Appendix Table C28. Time to event outcomes: Comparator, rhabdomyosarcoma Continued**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study (Investigator, country, year)** | **Record Number** | **Group (N)** | **Outcome\_2** | **1 yr\_2** | **2 yr\_2** | **3 yr\_2** | **4 yr TRM** | **5 yr\_2** | **Comment** |
| Breneman, USA, 2003 | 75360 | comparator (127) | FFS | ~69% | ~33% | 25% (17-33) | ~20% | ~20% | FFS influenced by distant metastasis in lymph nodes. OS influenced by number of metastatic sites |
| Carli, Italy, 1999 | 16010 | Comparator (44) | EFS | ~53% | ~30% | 19.2 (6.8-31.6) | ~20% | ~20% |   |
| McDowell, UK, 2010 | 75350 | Comparator (45) | Event free survival |   |   | 54.92% |   | 51.00% |   |
| Pappo, USA, 1999 | 48020 | Comparator (605) |   |   |   |   |   |   |   |
| Pappo, USA, 2001 | 47860 | Comparator (48) | failure Free | ~57% | 24% (13-36) | ~21% | ~21% |   |   |
| Sandler, USA, 2001 | 12810 | Comparator (152) | FFS | ~63% | ~36% | ~28% | ~28% | ~27% |   |
| Van Winkle, USA, 2005 | 43550 | Comparator(27) |   |   |   |   |   |   |   |
| Williams, Canada, 2004 | 9010 | Comparator (13) | Failure Free survival |   |   | 15% (-4-35) |   |   |   |